JASCAYD
LaunchNDAORALTABLETPriority Review
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
JASCAYD by Boehringer Ingelheim is 4 (pde4) with at least nine-fold preferential inhibition of the pde4b isoenzyme over pde4a, pde4c, and pde4d based on in vitro data. Approved for idiopathic pulmonary fibrosis (ipf) in adult patients, progressive pulmonary fibrosis (ppf) in adult patients. First approved in 2025.
Drug data last refreshed Yesterday
Mechanism of Action
4 (PDE4) with at least nine-fold preferential inhibition of the PDE4B isoenzyme over PDE4A, PDE4C, and PDE4D based on in vitro data. PDE4 hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP). Nerandomilast exerts both antifibrotic and immunomodulatory effects as PDE4B inhibition…
Worked on JASCAYD at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.